These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9800932)

  • 41. Quality audit of the guidelines for the use of RhD immunoglobulin in obstetrics: Are we getting it right?
    Glazebrook B; Akers C; Bielby L; Bastin K; Von Wielligh K; Daly J
    Aust N Z J Obstet Gynaecol; 2020 Aug; 60(4):504-508. PubMed ID: 32424867
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Causes and clinical consequences of Rhesus (D) haemolytic disease of the newborn: a study of a Scottish population, 1985-1990.
    Hughes RG; Craig JI; Murphy WG; Greer IA
    Br J Obstet Gynaecol; 1994 Apr; 101(4):297-300. PubMed ID: 8199074
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A case for the antenatal administration of anti-D immunoglobulin to primigravidae.
    Tovey LA; Taverner JM
    Lancet; 1981 Apr; 1(8225):878-81. PubMed ID: 6112301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and obstetric outcome of women with red cell antibodies in pregnancy at the Leeds Teaching Hospitals NHS Trust, West Yorkshire, England.
    Awowole I; Cohen K; Rock J; Sparey C
    Eur J Obstet Gynecol Reprod Biol; 2019 Jun; 237():89-92. PubMed ID: 31035121
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Altered strategy of prophylactic anti-D administration in pregnancy to cover term and post-term - a pilot study.
    Wikman A; Mörtberg A; Jalkesten E; Jansson Y; Karlsson A; Tiblad E; Ajne G
    Vox Sang; 2021 Oct; 116(9):1005-1011. PubMed ID: 33772800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multicentre trial of antepartum low-dose anti-D immunoglobulin.
    Lee D; Rawlinson VI
    Transfus Med; 1995 Mar; 5(1):15-9. PubMed ID: 7767393
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin.
    MacKenzie IZ; Roseman F; Findlay J; Thompson K; Jackson E; Scott J; Reed M
    BJOG; 2006 Jan; 113(1):97-101. PubMed ID: 16398777
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Red blood cell iso-immunisation in the Wellington area of New Zealand: the case for antenatal prophylaxis.
    Tuohy JF; Sangalli M; Kim L
    Aust N Z J Obstet Gynaecol; 2004 Oct; 44(5):458-9. PubMed ID: 15387870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical validation of routine antenatal anti-D prophylaxis questions the modelling predictions adopted by NICE for Rhesus D sensitisation rates: results of a longitudinal study.
    Mackenzie IZ; Roseman F; Findlay J; Thompson K; McPherson K
    Eur J Obstet Gynecol Reprod Biol; 2008 Jul; 139(1):38-42. PubMed ID: 18243487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Prevention of Rh D alloimmunization in the first trimester of the pregnancy: French College of Obstetricians and Gynecologists guidelines for clinical practice].
    Vigoureux S; Maurice P; Sibiude J; Garabedian C; Sananès N
    Gynecol Obstet Fertil Senol; 2024; 52(7-8):446-453. PubMed ID: 38417789
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of anti-D immunoglobulin in the treatment of threatened miscarriage in the accident and emergency department.
    Weinberg L
    Emerg Med J; 2001 Nov; 18(6):444-7. PubMed ID: 11696491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy.
    Koelewijn JM; de Haas M; Vrijkotte TG; Bonsel GJ; van der Schoot CE
    Transfusion; 2008 Aug; 48(8):1721-9. PubMed ID: 18507749
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Prevention of Rh (D) alloimmunization in Rh (D) negative women in pregnancy and after birth of Rh (D) positive infant].
    L'ubuský M; Procházka M; Krejcová L; Vetr M; Santavý J; Kudela M
    Ceska Gynekol; 2006 May; 71(3):173-9. PubMed ID: 16768042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is antenatal antibody screening worthwhile in the Zimbabwean population?
    Cakana AZ; Ngwenya L
    Cent Afr J Med; 2000 Feb; 46(2):38-41. PubMed ID: 14674207
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Rh-prophylaxis or not? Obstetric departments should make decisions if there are medical reasons which justify the treatment].
    Messeter L
    Lakartidningen; 2000 Dec; 97(51-52):6030-3. PubMed ID: 11195439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Haemolytic disease of the newborn--the changing scene.
    Tovey LA
    Br J Obstet Gynaecol; 1986 Sep; 93(9):960-6. PubMed ID: 3094573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
    Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
    BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Costs and benefits of non-invasive fetal RhD determination.
    Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Hemolytic disease of the newborn has not vanished from Finland--routine protection of RhD negative mothers during pregnancy is justifiable].
    Sainio S; Kuosmanen M
    Duodecim; 2012; 128(2):151-7. PubMed ID: 22372070
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An increased risk for non allo-immunization related intrauterine fetal death in RhD-negative patients.
    Ben-David G; Sheiner E; Levy A; Erez O; Mazor M
    J Matern Fetal Neonatal Med; 2008 Apr; 21(4):255-9. PubMed ID: 18330822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.